Otsuka Holdings Co., Ltd.

4578.T·Tokyo·Healthcare
Compare
12,425.00+520.00 (+4.37%)today
At close: Nov 5, 3:30 PM JST · May be delayed up to 20 min · JPY

Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close11,905.00
Open12,165.00
Day range12,060.0012,715.00
52-week range8,083.0012,795.00
Off day high−2.28%
Off 52-week high−2.89%
Volume2.09M
Avg. volume (3M)1.26M
Market cap6.51T
EPS (TTM)732.37
Forward P/E23.93
P/E ratio (TTM)16.97
Dividend yield1.68% (200.00)
Beta (5Y)-0.06
Shares outstanding523.91M
Short interest—
Earnings dateOct 30, 2026
Analyst target14,630.77
Profit margin14.40%

Against its peers

Compare in full ›
4578.T AZN ON4.F CUP.F D4S.F OFK.F
Market cap 6.51T 293.14B 6.28B 65.86B 31.06B 14.28B
P/E (TTM) 17.0 26.7 15.4 24.0 20.3 21.7
Forward P/E 23.9 16.7 — 0.3 46.1 —
Price/book 2.0 5.7 1.3 5.6 3.1 10.2
Dividend yield 1.68% 1.69% 3.63% 1.93% 3.57% 1.82%
1-year change +41.09% +12.81% +18.01% −1.62% −17.43% +71.74%
Today +4.37% +2.79% +4.90% +4.33% +5.64% +2.99%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.

Latest news

All 4578.T news ›
otsuka-us.com·Positive

Otsuka Presents Landmark Final Phase 3 VISIONARY Results at ASN Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilized Kidney Function and Reduced Risk of Disease Progression and Kidney Failure, Redefining Treatment Paradigm in IgA Nephropathy | Otsuka US

You will now be redirected to www.otsuka-us.com in 20 seconds. Top panel from New England Journal of Medicine, Rizk DV, Barratt J, Suzuki Y, et al, Sibeprenlimab in IgA Nephropathy ─ Final Phase 3 Trial Analysis, Volume No. 396; page…

From the 4Search news index, newest first.

In the news

8mentions in 30 days
8with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance